VBL Therapeutics to Present at the 29th Annual ROTH Conference
Mar 07, 2017 12:00 pm UTC| Business
TEL AVIV, Israel, March 07, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today...
Brookfield to Acquire Controlling Stake and Assume Sponsorship of TerraForm Power
Mar 07, 2017 11:55 am UTC| Business
Brookfield to become cornerstone investor in TerraForm Power with 51% ownershipTerraForm Power Class A shareholders to receive $11.46 per share in cash with option for shareholders to elect shares in order to participate...
Brookfield to Acquire TerraForm Global
Mar 07, 2017 11:55 am UTC| Business
BETHESDA, Md., March 07, 2017 -- TerraForm Global, Inc. (Nasdaq:GLBL) (“TerraForm Global” or the “Company”), an owner and operator of clean energy power plants, today announced that it has entered into a definitive...
Buckeye Partners, L.P.’s 2016 Schedule K-1 Tax Packages Are Now Available
Mar 07, 2017 11:50 am UTC| Business
HOUSTON, March 07, 2017 -- Buckeye Partners, L.P. (“Buckeye”) (NYSE:BPL) announced today that the 2016 unitholder tax packages are available online. Investors can obtain their tax packages, which include Schedule K-1,...
Middle East In-Vitro Diagnostic (IVD) Market Report
Mar 07, 2017 11:48 am UTC| Business
Dublin, March 07, 2017 -- Research and Markets has announced the addition of the "IVD in the Middle East (Egypt, Turkey, Saudi Arabia, United Arab Emirates, Israel, Jordan, Other Mideast)" report to...
World Mass Spectrometry in Clinical Testing Applications Market Report 2017
Mar 07, 2017 11:48 am UTC| Business
Dublin, March 07, 2017 -- Research and Markets has announced the addition of the "The Market for Mass Spectrometry in Clinical Testing Applications" report to their offering. The Market...
Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results
Mar 07, 2017 11:45 am UTC| Business
STAMFORD, Conn., March 07, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported...